We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VEOZA (Astellas Pharma Australia Pty Ltd)
Product name
VEOZA
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
fezolinetant
Registration type
NCE/NBE
Indication
VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see section 5.1 Pharmacodynamic Properties – Clinical Trials).